Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed‐ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan‐L trial

AIMS: To assess the impact of baseline characteristics on clinical outcomes in the LixiLan‐L trial, a randomized open‐label trial designed to evaluate the efficacy and safety of iGlarLixi, a novel fixed‐ratio combination of insulin glargine 100 U (iGlar) plus lixisenatide, in comparison with iGlar o...

Descripción completa

Detalles Bibliográficos
Autores principales: Wysham, Carol, Bonadonna, Riccardo C., Aroda, Vanita R., Puig Domingo, Manuel, Kapitza, Christoph, Stager, William, Yu, Christine, Niemoeller, Elisabeth, Souhami, Elisabeth, Bergenstal, Richard M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638095/
https://www.ncbi.nlm.nih.gov/pubmed/28386990
http://dx.doi.org/10.1111/dom.12961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638095/
https://www.ncbi.nlm.nih.gov/pubmed/28386990
http://dx.doi.org/10.1111/dom.12961

Ejemplares similares